



July 16, 2024

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

Scrip Code: **543271**

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051
Trading Symbol: **JUBLINGREA**

Subject: Outcome of Board Meeting held on July 16, 2024

Ref.: Regulation 33 and Regulation 52(4) read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sirs,

Pursuant to the provisions of Regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations") and SEBI Circular No. SEBI/HO/DDHS/DDHS_Div1/P/CIR /2022/0000000103 (as amended), we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on Tuesday, July 16, 2024 at 12:15 p.m. that concluded at 02:55 p.m., inter-alia approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2024 and Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter;

Pursuant to applicable provisions of the Listing Regulations, we enclose the following:

1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2024;
2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter;

We request you to take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary

Encl. as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657

Walker Chandiook & Co LLP

Plot No. 19A, 2nd floor,
Sector - 16A,
Noida - 201 301
Uttar Pradesh, India

T +91 120 485 5999
F +91 120 485 5902

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Jubilant Ingrevia Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30 June 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended).
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended). Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review report of the other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement also includes the Group's share of net profit after tax of ₹ 7.81 lakhs and total comprehensive income of ₹ 7.81 lakhs for the quarter ended on 30 June 2024, as considered in the Statement, in respect of an associate, whose interim financial information has not been reviewed by us. This interim financial information has been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

For Walker Chandiook & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Madhu Sudan
Madhu Sudan Malpani
Partner
Membership No. 517440



UDIN: 24517440BKGUAS5168

Place: Noida
Date: 16 July 2024

Walker Chandiook & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Annexure 1

List of entities included in the Statement:

S. No.	Name	Relationship with the Holding Company
1	Jubilant Infrastructure Limited	Subsidiary
2	Jubilant Agro Sciences Limited	Subsidiary
3	Jubilant Life Sciences (USA) Inc.	Subsidiary
4	Jubilant Life Sciences NV	Subsidiary
5	Jubilant Life Sciences International Pte. Limited	Subsidiary
6	Jubilant Life Sciences (Shanghai) Limited	Subsidiary
7	Jubilant Ingrevia Employee Welfare Trust	Subsidiary
8	Mister Veg Foods Private Limited	Associate
9	AMP Energy Green Fifteen Private Limited	Associate



Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Consolidated Unaudited Financial Results for the Quarter Ended 30 June 2024

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended		Year Ended	
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2024	2024	2023	2024
1	Revenue from operations				
	a) Sales/Income from operations	101045	106024	106866	410045
	b) Other operating income	1389	1420	636	3535
	Total revenue from operations	102434	107444	107502	413580
2	Other income	957	950	850	3530
3	Total Income (1+2)	103391	108394	108352	417110
4	Expenses				
	a) Cost of materials consumed	53199	48762	57891	204034
	b) Purchases of stock-in-trade	740	1339	1335	4910
	c) Changes in inventories of finished goods, stock-in-trade and work-in progress	(1080)	9492	(4959)	5314
	d) Employee benefits expense	10150	8594	9344	38395
	e) Finance costs	1427	1362	1146	5266
	f) Depreciation and amortisation expense	3888	3572	3230	13617
	g) Other expenses:				
	- Power and fuel expense	11791	11758	15939	52115
	- Others	16681	18375	16287	66700
	Total expenses	96796	103254	100213	390351
5	Profit before share of profit/(loss) of an associate (3-4)	6595	5140	8139	26759
6	Share of profit/(loss) of an associate	8	(5)	(8)	2
7	Profit before tax (5+6)	6603	5135	8131	26761
8	Tax expense				
	- Current tax	1248	2233	1676	6362
	- Deferred tax charge/(credit)	481	(23)	696	2110
9	Net profit for the period/year (7-8)	4874	2925	5759	18289
10	Other comprehensive income (OCI)				
	i) a) Items that will not be reclassified to profit or loss	195	539	33	310
	b) Income tax relating to items that will not be reclassified to profit or loss	(1)	(115)	6	(10)
	ii) a) Items that will be reclassified to profit or loss	(57)	(192)	(68)	10
	b) Income tax relating to items that will be reclassified to profit or loss	25	99	14	41
11	Total comprehensive income for the period/year (9+10)	5036	3256	5744	18640
	Net profit attributable to:				
	Owners of the Company	4874	2925	5759	18289
	Non-controlling interests	-	-	-	-
	Other comprehensive Income attributable to:				
	Owners of the Company	162	331	(15)	351
	Non-controlling interests	-	-	-	-
	Total comprehensive Income attributable to:				
	Owners of the Company	5036	3256	5744	18640
	Non-controlling interests	-	-	-	-
12	Earnings per share of ₹ 1 each (not annualised for the quarters)				
	Basic (₹)	3.08	1.85	3.63	11.56
	Diluted (₹)	3.08	1.85	3.63	11.55
13	Paid-up equity share capital (face value per share ₹ 1)	1580	1580	1580	1580
14	Reserves excluding revaluation reserves (other equity)				272167
	See accompanying notes to the Consolidated Unaudited Financial Results				



SIGNED FOR
IDENTIFICATION
PURPOSE ONLY



Jubilant Ingrevia Limited

Note 1: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter Ended 30 June 2024

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2024	2024	2023	2024
1	Segment revenue				
	a. Speciality Chemicals	47533	53265	43908	184905
	b. Nutrition & Health Solutions	18634	16461	20227	68011
	c. Chemical Intermediates	41028	44050	51118	189704
	Total	107195	113776	115253	442620
	Less : Inter segment revenue	4761	6332	7751	29040
	Total revenue from operations	102434	107444	107502	413580
	a. Speciality Chemicals	43066	47527	36377	158554
	b. Nutrition & Health Solutions	18611	16450	20227	68000
	c. Chemical Intermediates	40757	43467	50898	187026
	Total	102434	107444	107502	413580
2	Segment results (profit before tax and interest)				
	a. Speciality Chemicals	6250	4535	3871	16838
	b. Nutrition & Health Solutions	1962	566	1356	4862
	c. Chemical Intermediates	2354	3197	4944	15876
	Total	10566	8298	10171	37576
	Less: i. Interest (finance costs)	1427	1362	1146	5266
	ii. Un-allocable expenditure (net of un-allocable income)	2536	1801	894	5549
	Profit before tax	6603	5135	8131	26761
3	Segment assets				
	a. Speciality Chemicals	264301	267095	250505	267095
	b. Nutrition & Health Solutions	51122	51829	50610	51829
	c. Chemical Intermediates	151222	138551	140304	138551
	d. Unallocable corporate assets	13631	15714	11635	15714
	Total segment assets	480276	473189	453054	473189
4	Segment liabilities				
	a. Speciality Chemicals	40937	40988	47324	40988
	b. Nutrition & Health Solutions	10360	12320	9162	12320
	c. Chemical Intermediates	51975	48640	52350	48640
	d. Unallocable corporate liabilities	97943	97494	76091	97494
	Total segment liabilities	201215	199442	184927	199442



SIGNED FOR
IDENTIFICATION
PURPOSE ONLY



Jubilant Ingrevia Limited

Note 2: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


(Consolidated)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2024	2024	2023	2024
1	Debt service coverage ratio (in times)# <i>Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)</i> {EBITDA: Profit before tax + depreciation and amortisation expense + finance costs}	8.35	7.39	10.91	8.67
2	Interest service coverage ratio (in times) <i>Definition: EBITDA/finance costs</i>	8.35	7.39	10.91	8.67
3	Bad debts to account receivable ratio (%)# <i>Definition: Bad debts/average of opening and closing trade receivables</i> {Bad debts: Impairment balance as per statements of profit and loss}	(0.04%)	0.15%	0.03%	0.43%
4	Debtors turnover (in times)# <i>Definition: Revenue from operations/average of opening and closing trade receivables</i>	1.80	2.13	2.21	7.64
5	Inventory turnover (in times)# <i>Definition: Cost of goods sold/average of opening and closing inventories</i>	0.56	0.59	0.49	2.17
6	Operating margin (%) <i>Definition: Operating profit/revenue from operations</i> {Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses} {Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress}	6.90%	5.17%	7.85%	6.89%
7	Net profit margin (%) <i>Definition: Net profit/total income</i>	4.71%	2.70%	5.31%	4.38%
8	Net worth (In ₹ Lakhs) {Net worth: Equity share capital + other equity}	279061	273747	268127	273747
9	Debt equity ratio (in times) <i>Definition: Net debts/net worth</i> {Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}	0.24	0.24	0.18	0.24
10	Current ratio (in times) <i>Definition: Current assets/current liabilities</i>	1.36	1.38	1.36	1.38
11	Long term debt to working capital (in times) <i>Definition: Long term debt/working capital</i> {Long term debt: Long term borrowings (gross of transaction costs)} {working capital: Current assets - current liabilities}	0.95	0.91	0.29	0.91
12	Current liability ratio (in times) <i>Definition: Current liabilities/total liabilities</i>	0.65	0.64	0.77	0.64
13	Total debts to total assets (in times) <i>Definition: Total debts/total assets</i> {Total debts: Long term borrowings (gross of transaction costs) + short term borrowings}	0.15	0.15	0.12	0.15

not annualised for the quarters



**SIGNED FOR
IDENTIFICATION
PURPOSE ONLY**



Notes to consolidated unaudited financial results (cont'd):

3. These consolidated unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

4. As on 30 June 2024, the Holding Company has outstanding unsecured listed commercial papers (CPs) of ₹ 10000 lakhs. These CPs are listed on the National Stock Exchange of India. Details of CPs are as follows:

ISIN No.	Issue date	Due date of repayment	Redemption amount
INE0BY014284	25 June 2024	25 July 2024	₹ 10000 lakhs

5. The figures for the quarter ended 31 March 2024, as reported in the consolidated financial results, are the balancing figures between the audited figures for the year ended 31 March 2024 and the published year to date figures for 31 December 2023, which were subjected to limited review by the statutory auditors.
6. Previous periods figures have been regrouped/reclassified to conform to the current period classification.
7. The above consolidated unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 16 July 2024. These results have been subjected to limited review by the statutory auditors of the Company. The review report of the statutory auditor is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on consolidated financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

Place : Noida
Date : 16 July 2024

For Jubilant Ingrevia Limited



Deepak Jain
CEO & Managing Director



**SIGNED FOR
IDENTIFICATION
PURPOSE ONLY**



Walker Chandiook & Co LLP

Walker Chandiook & Co LLP

Plot No. 19A, 2nd floor,
Sector - 16A,
Noida - 201 301
Uttar Pradesh, India

T +91 120 485 5999
F +91 120 485 5902

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Company') for the quarter ended 30 June 2024, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended).
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended). Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani

Partner

Membership No. 517440



UDIN: 24517440BKGUAR9385

Place: Noida

Date: 16 July 2024

Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30 June 2024

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2024	2024	2023	2024
1	Revenue from operations				
	a) Sales/Income from operations	95528	102277	102436	395214
	b) Other operating income	1381	1397	636	3511
	Total revenue from operations	96909	103674	103072	398725
2	Other income	922	977	961	3552
3	Total income (1+2)	97831	104651	104033	402277
4	Expenses				
	a) Cost of materials consumed	53032	48633	57891	203905
	b) Purchases of stock-in-trade	740	832	1335	4403
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(121)	10211	(5563)	6688
	d) Employee benefits expense	9162	7656	8365	34279
	e) Finance costs	1669	1665	1528	6629
	f) Depreciation and amortisation expense	3633	3452	3169	13314
	g) Other expenses:				
	- Power and fuel expense	12033	12019	16239	53325
	- Others	13249	14940	13391	55834
	Total expenses	93397	99408	96355	378377
5	Profit before tax (3-4)	4434	5243	7678	23900
6	Tax expense				
	- Current tax	955	2067	1396	5286
	- Deferred tax charge	202	78	800	2369
7	Net profit for the period/year (5-6)	3277	3098	5482	16245
8	Other comprehensive income (OCI)				
	i) a) Items that will not be reclassified to profit or loss	(35)	191	(36)	(139)
	b) Income tax relating to items that will not be reclassified to profit or loss	9	(80)	13	35
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
9	Total comprehensive income for the period/year (7+8)	3251	3209	5459	16141
10	Earnings per share of ₹ 1 each (not annualised for the quarters)				
	Basic (₹)	2.06	1.94	3.44	10.20
	Diluted (₹)	2.06	1.94	3.44	10.20
11	Paid-up equity share capital (face value per share ₹ 1)	1593	1593	1593	1593
12	Reserves excluding revaluation reserves (other equity)				223113
	See accompanying notes to the Standalone Unaudited Financial Results				



SIGNED FOR
IDENTIFICATION
PURPOSE ONLY



Jubilant Ingrevia Limited

Note 1: Standalone Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter Ended 30 June 2024

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2024	2024	2023	2024
1	Segment revenue				
	a. Speciality Chemicals	45287	53194	44614	182612
	b. Nutrition & Health Solutions	17250	14226	17620	67088
	c. Chemical Intermediates	39133	42586	48589	178065
	Total	101670	110006	110823	427765
	Less: Inter segment revenue	4761	6332	7751	29040
	Total revenue from operations	96909	103674	103072	398725
	a. Speciality Chemicals	40820	47456	37083	156261
	b. Nutrition & Health Solutions	17227	14215	17620	67077
	c. Chemical Intermediates	38862	42003	48369	175387
	Total	96909	103674	103072	398725
2	Segment results (profit before tax and interest)				
	a. Speciality Chemicals	5897	4870	3601	17586
	b. Nutrition & Health Solutions	1568	497	1667	5222
	c. Chemical Intermediates	1166	3312	4818	13239
	Total	8631	8679	10086	36047
	Less: i. Interest (finance costs)	1669	1665	1528	6629
	ii. Un-allocable expenditure (net of un-allocable income)	2528	1771	880	5518
	Profit before tax	4434	5243	7678	23900
3	Segment assets				
	a. Speciality Chemicals	237609	238512	233124	238512
	b. Nutrition & Health Solutions	38705	37074	39375	37074
	c. Chemical Intermediates	125791	122727	134069	122727
	d. Unallocable corporate assets	33919	35727	26626	35727
	Total segment assets	436024	434040	433194	434040
4	Segment liabilities				
	a. Speciality Chemicals	40241	38760	46128	38760
	b. Nutrition & Health Solutions	12590	13464	12017	13464
	c. Chemical Intermediates	48682	49788	62544	49788
	d. Unallocable corporate liabilities	106276	107322	91140	107322
	Total segment liabilities	207789	209334	211829	209334



SIGNED FOR
IDENTIFICATION
PURPOSE ONLY



Jubilant Ingrevia Limited

Note 2: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


(Standalone)

Sr. No.	Particulars	Quarter Ended		Year Ended	
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2024	2024	2023	2024
1	Debt service coverage ratio (in times)# <i>Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)</i> <i>{EBITDA: Profit before tax + depreciation and amortisation expense + finance costs}</i>	5.83	6.22	8.10	6.61
2	Interest service coverage ratio (in times) <i>Definition: EBITDA/finance costs</i>	5.83	6.22	8.10	6.61
3	Bad debts to account receivable ratio (%)# <i>Definition: Bad debts/average of opening and closing trade receivables</i> <i>{Bad debts: Impairment balance as per statements of profit and loss}</i>	(0.04%)	0.15%	0.03%	0.44%
4	Debtors turnover (in times)# <i>Definition: Revenue from operations/average of opening and closing trade receivables</i>	1.75	2.10	2.10	7.52
5	Inventory turnover (in times)# <i>Definition: Cost of goods sold/average of opening and closing inventories</i>	0.69	0.73	0.56	2.60
6	Operating margin (%) <i>Definition: Operating profit/revenue from operations</i> <i>{Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses}</i> <i>{Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress}</i>	5.35%	5.72%	8.00%	6.77%
7	Net profit margin (%) <i>Definition: Net profit/total income</i>	3.35%	2.96%	5.27%	4.04%
8	Net worth (In ₹ Lakhs) <i>{Net worth: Equity share capital + other equity}</i>	228235	224706	221365	224706
9	Debt equity ratio (in times) <i>Definition: Net debts/net worth</i> <i>{Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}</i>	0.36	0.36	0.31	0.36
10	Current ratio (in times) <i>Definition: Current assets/current liabilities</i>	1.20	1.11	1.06	1.11
11	Long term debt to working capital (in times) <i>Definition: Long term debt/working capital</i> <i>{Long term debt: Long term borrowings (gross of transaction costs)}</i> <i>{working capital: Current assets - current liabilities}</i>	2.07	2.71	1.52	2.71
12	Current liability ratio (in times) <i>Definition: Current liabilities/total liabilities</i>	0.61	0.66	0.79	0.66
13	Total debts to total assets (in times) <i>Definition: Total debts/total assets</i> <i>{Total debts: Long term borrowings (gross of transaction costs) + short term borrowings}</i>	0.19	0.19	0.16	0.19

not annualised for the quarters



SIGNED FOR
IDENTIFICATION
PURPOSE ONLY



Notes to standalone unaudited financial results (cont'd):

3. These standalone unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

4. As on 30 June 2024, the Company has outstanding unsecured listed commercial papers (CPs) of 10000 lakhs. These CPs are listed on the National Stock Exchange of India. Details of CPs are as follows:

ISIN No.	Issue date	Due date of repayment	Redemption amount
INE0BY014284	25 June 2024	25 July 2024	₹ 10000 lakhs

5. The figures for the quarter ended 31 March 2024, as reported in the standalone financial results, are the balancing figures between the audited figures for the year ended 31 March 2024 and the published year to date figures for 31 December 2023, which were subjected to limited review by the statutory auditor.

6. The above standalone unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 16 July 2024. These results have been subjected to limited review by the statutory auditor of the Company. The review report of the statutory auditor is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on standalone financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited



Deepak Jain
CEO & Managing Director

Place : Noida

Date : 16 July 2024



**SIGNED FOR
IDENTIFICATION
PURPOSE ONLY**

